Obgyn · Year 3 · from Obgyn
Case 1: Vasomotor Symptoms and Hormone Therapy Initiation
Patient Demographics
- Age: 52 years
- Sex: Female
- Occupation: Accountant
Chief Complaint
"I'm having terrible hot flashes that are ruining my sleep and affecting my work."
History of Present Illness
The patient presents with a 14-month history of progressively worsening hot flashes and night sweats. She describes sudden episodes of intense heat beginning in her chest and rising to her face, accompanied by flushing, profuse sweating, and palpitations, lasting 2 to 4 minutes each. She estimates she has 10 to 12 hot flashes during the day and 4 to 5 night sweats that wake her from sleep. The night sweats require her to change her pajamas and bedsheets multiple times weekly. She reports significant sleep disruption with an average of only 4 to 5 hours of fragmented sleep per night. She is experiencing fatigue, irritability, difficulty concentrating at work, and depressed mood. Her last menstrual period was 13 months ago. Prior to the cessation of menses, she had 6 months of irregular cycles with intervals ranging from 21 to 60 days.
Past Medical History
- No significant medical history
- No prior surgeries
- No history of thromboembolism
- No breast cancer or breast biopsies
- Menarche at age 13, previously regular cycles
- G2P2, two uncomplicated vaginal deliveries
Family History
- Mother alive at 78, history of osteoporosis
- No family history of breast cancer, ovarian cancer, or thromboembolism
- Father deceased at 72 from myocardial infarction
Medications
- Multivitamin daily
- Calcium 500 mg with vitamin D 400 IU daily
Physical Examination Findings
- Vital Signs: BP 128/78 mmHg, HR 76 bpm, BMI 26 kg/m2
- General: Well-appearing woman in no acute distress
- Thyroid: Normal size, no nodules
- Breast: No masses, no nipple discharge, no axillary lymphadenopathy
- Cardiovascular: Regular rate and rhythm, no murmurs
- Abdomen: Soft, non-tender, no hepatosplenomegaly
- Pelvic: External genitalia with mild labial atrophy, vaginal mucosa pale and dry with loss of rugae, cervix atrophic-appearing, uterus small and non-tender, ovaries not palpable
Diagnostic Workup
- FSH: 68 IU/L (elevated, consistent with menopause)
- Estradiol: 12 pg/mL (low, postmenopausal range)
- TSH: 2.4 mIU/L (normal, ruling out thyroid dysfunction)
- Lipid Panel: Total cholesterol 218 mg/dL, LDL 138 mg/dL, HDL 52 mg/dL, Triglycerides 142 mg/dL
- Fasting Glucose: 94 mg/dL (normal)
- Mammogram: BI-RADS 1, negative, performed 8 months ago
- Pap Smear: Normal, HPV negative, performed 2 years ago
Diagnosis
Menopause with moderate-to-severe vasomotor symptoms significantly impacting quality of life
- Meets diagnostic criteria: 12 months of amenorrhea at appropriate age
- Laboratory confirmation with elevated FSH and low estradiol
- Patient is within the "window of opportunity" (within 10 years of menopause onset, under age 60)
Management Plan
Discussion of Treatment Options:
Hormone Therapy Considerations:
- Patient is an appropriate candidate for systemic hormone therapy:
- Intact uterus present (requires combined estrogen-progestogen)
- Within window of opportunity (age 52, 1 year postmenopause)
- No absolute contraindications
- Moderate-to-severe symptoms significantly impacting quality of life
Benefits discussed:
- 75% reduction in hot flash frequency and severity
- Improvement in sleep quality
- Prevention of bone loss
- Improvement in vaginal atrophy symptoms
- Potential mood and quality of life benefits
Risks discussed:
- Small increased risk of VTE (approximately doubled with oral; less with transdermal)
- Small increased risk of stroke (primarily with oral estrogen)
- Breast cancer risk with combined therapy increases after approximately 5 years of use
- Gallbladder disease risk with oral estrogen
Selected Treatment Regimen:
- Transdermal estradiol 0.05 mg/day patch (applied twice weekly)
- Transdermal selected due to:
- Lower VTE risk compared to oral
- No first-pass hepatic effect (better for her borderline lipids)
- Steady-state hormone delivery
- Micronized progesterone (Prometrium) 100 mg orally at bedtime nightly (continuous combined regimen)
- Micronized progesterone selected for:
- More favorable metabolic profile than synthetic progestins
- Sedative properties beneficial for her insomnia
- Continuous combined regimen to achieve amenorrhea
Alternative discussed: Levonorgestrel IUD for endometrial protection if she prefers avoiding oral progestogen
Lifestyle Recommendations:
- Avoid known triggers: alcohol, caffeine, spicy foods, hot beverages
- Layer clothing for easy removal during hot flashes
- Keep bedroom cool (65-68 degrees F)
- Regular aerobic exercise (150 minutes per week)
- Stress reduction techniques
Follow-up Plan:
- Return in 3 months to assess symptom response and side effects
- Mammogram annually
- If inadequate response at 3 months, consider increasing to 0.075 mg transdermal patch
- Annual reassessment of need for continued therapy
- Bone density screening at age 65 (or earlier if risk factors develop)
Counseling Points:
- Hormone therapy is the most effective treatment for vasomotor symptoms
- Start at low dose and titrate to symptom control
- No arbitrary time limit on duration; annual reassessment recommended
- Transient breast tenderness and vaginal spotting may occur initially
- Report any unexpected vaginal bleeding after the first 6 months
Clinical Image
Image Description: Diagram illustrating the spectrum of menopausal symptoms including vasomotor symptoms (hot flashes, night sweats), genitourinary symptoms (vaginal dryness, urinary frequency), psychological symptoms (mood changes, sleep disturbance, cognitive changes), and musculoskeletal symptoms (joint pain). The diagram demonstrates the multi-system effects of estrogen deficiency.
Attribution: Image adapted from Wikimedia Commons, "Symptoms of menopause (vector).svg" by Mikael Haggstrom. Licensed under CC BY-SA 4.0. Source: https://commons.wikimedia.org/wiki/File:Symptoms_of_menopause_(vector).svg